🔄 Post-Stroke Rehabilitation Intensity Dosing Simulator

Acute Phase Assessment — Early Mobilization and Baseline Deficit Mapping

The rehabilitation dosing decision begins before a formal exercise prescription exists. Within the first 24–48 hours after stroke onset, clinicians balance the benefits of early mobilization against medical stability, while a structured battery of functional assessments maps exactly which domains — motor, speech, cognitive, swallowing — are impaired and by how much. This baseline becomes the anchor against which every future dosing decision is measured.

• 24–48 h: Early mobilization window (from symptom onset, if stable)
• <24 h: AVERT trial very-early group (showed worse outcomes if too intense)
• NIHSS, FMA, ARAT: Common assessment scales (motor & global deficit batteries)
• ~70–80%: Patients with upper-limb deficit (at initial presentation)

Why timing of first mobilization matters

Early mobilization after stroke was long assumed to be uniformly beneficial — get patients out of bed as soon as possible to prevent complications like pneumonia, deep vein thrombosis, and deconditioning. The AVERT (A Very Early Rehabilitation Trial) landmark study complicated this picture: very early, frequent, high-dose mobilization (within 24 hours) was associated with worse outcomes at 3 months compared to usual care.

The resolution is a dose-dependent one: mobilization itself is beneficial, but the frequency and intensity of very early sessions matters. Current guidelines generally recommend beginning mobilization within 24–48 hours in medically stable patients, with lower-intensity, shorter, more frequent sessions in the first days, progressing in dose as stability and tolerance improve.

Medical stability screening before mobilization checks: hemodynamic stability, absence of ongoing hemorrhage extension, adequate oxygenation, and no uncontrolled intracranial pressure — all before any dosing decision is even made.

AVERT reframed early mobilization from "more is always better" to a dose-response question — the same principle that governs every later stage of rehabilitation intensity prescription.

Mapping baseline functional deficits

Before any intensity can be prescribed, the deficit must be quantified. A standard acute-phase battery spans multiple domains, each independently dosed later:

• Global severity — NIH Stroke Scale (NIHSS): 0–42 point scale across consciousness, gaze, motor, sensory, language • Upper-limb motor — Fugl-Meyer Assessment (FMA-UE, 0–66) and Action Research Arm Test (ARAT, 0–57) • Lower-limb / gait — Fugl-Meyer lower extremity, 10-meter walk test, Functional Ambulation Category • Speech and language — aphasia screening (e.g., Frenchay), dysarthria assessment • Swallowing — bedside swallow screen before any oral intake • Cognition — Montreal Cognitive Assessment (MoCA) once alert enough to test

Each domain's severity independently informs which discipline (PT, OT, speech-language pathology) leads dosing decisions, and how aggressive early intensity can safely be.

From assessment to prescription

The acute assessment does not itself set a dose — it establishes the reference point. A patient with severe FMA-UE impairment (dense hemiplegia) and a patient with mild impairment (reduced fine motor control only) will follow completely different dosing trajectories even though both begin rehabilitation on day 1–2.

This stage also flags contraindications and precautions that will shape every later intensity decision: cardiac instability, uncontrolled blood pressure, seizure risk, cognitive/behavioral barriers to participation, and fatigue tolerance — all captured before the dose-response prescription process begins in earnest.

The Dose-Response Principle — Repetition and Intensity Drive Neuroplasticity

Motor recovery after stroke is not simply the passive return of lost function — it is an active, use-dependent process of cortical reorganization. Decades of animal studies and a growing body of human trials converge on a central principle: task-specific practice, delivered at sufficient repetition and intensity, drives greater neuroplastic change and better functional outcomes than low-dose or generic exercise — but the relationship is not linear indefinitely.

• ~400–600/day: Animal model reps for cortical map change (skilled reaching, rodent studies)
• ~30–45/session: Typical usual-care UE reps (observed in early trials)
• 300+/session: High-dose UE trial reps (e.g. EXCITE, task-specific protocols)
• LTP-like plasticity: Key mechanism (synaptic strengthening w/ repeated use)

Evidence from animal models of motor learning

Foundational work in rodent and non-human primate models established that skilled motor practice — not merely movement, but movement directed at a specific task — reorganizes the motor cortex. Animals trained on skilled reaching tasks show expanded cortical representation of the trained limb, increased synaptic density, and dendritic branching in motor cortex, but only when practice involves hundreds of repetitions of a meaningfully difficult task.

Simple, repetitive, non-skilled movement (e.g., passive range of motion) does not produce the same cortical map reorganization, even at high repetition counts. This distinction — skilled, task-specific, effortful practice versus generic movement — is central to modern rehabilitation dosing and is often described as the difference between "use" and "skilled use."

Translating the principle to human stroke rehabilitation

Early observational studies of usual-care stroke rehabilitation found strikingly low repetition counts — often 30–45 upper-limb repetitions per session, orders of magnitude below the doses associated with cortical reorganization in animal models. This "therapy gap" motivated a generation of high-dose task-specific trials.

Trials such as EXCITE (constraint-induced movement therapy) and various robotic and self-directed practice protocols have delivered several hundred repetitions per session and demonstrated superior motor gains compared to usual, lower-dose care — though the translation from animal-model repetition counts to precise human dosing thresholds remains an active area of research, and effect sizes vary by impairment severity and time since stroke.

A recurring finding across upper-limb trials: hundreds of task-specific repetitions per day, not tens, are typically needed before a measurable dose-response signal on standardized motor scales emerges.

The dose-response curve is not linear indefinitely

The dose-response relationship in rehabilitation resembles an inverted-U or plateauing curve rather than a straight line: benefit rises with dose across the low-to-moderate range, the rate of additional benefit slows as dose increases further, and at very high doses — especially without adequate rest — quality of movement, adherence, and even safety can decline (explored in Stage 4).

This is precisely why "more is always better" is an oversimplification, and why intensity prescription (Stage 3) must consider frequency, duration, and repetitions together rather than maximizing any single dimension in isolation.

Intensity Prescription — Frequency, Duration, and Repetitions Across Disciplines

Translating the dose-response principle into an actual therapy schedule requires specifying three interacting dimensions: how often (sessions per week), how long (minutes per session), and how much task-specific work occurs within that time (repetitions per session). These parameters are set jointly and differ by discipline — physical therapy, occupational therapy, and speech-language pathology each have their own dosing literature and targets.

• 5–6 days/wk: Typical inpatient rehab frequency (multidisciplinary therapy)
• 100s of reps/day: UE task-specific target (for meaningful motor gains)
• 30–60 min: Typical session length (per discipline, per session)
• ≥5–10 h/wk: Aphasia therapy intensive dose (higher-intensity protocols)
• : ()

Frequency — sessions per week

Frequency describes how often therapy sessions occur. Inpatient rehabilitation facilities typically deliver multidisciplinary therapy five to six days per week across PT, OT, and speech-language pathology as indicated. Outpatient and community-based programs vary far more widely — from one to two sessions per week in resource-limited settings to daily intensive programs in specialized clinics or research protocols.

Higher frequency alone is not synonymous with higher total dose if session duration or repetition intensity is reduced to compensate — frequency must be considered jointly with duration and repetitions, not as an independent lever.

Duration — minutes per session

Session duration is typically 30–60 minutes per discipline in standard practice, though intensive protocols in trials have used longer sessions (60–90+ minutes) or multiple sessions per day. Duration must be tolerable: cognitive and physical fatigue, cardiovascular reserve, and attention span (particularly relevant for cognitive-communication and speech therapy) all cap how long a single session can productively run before returns diminish within-session.

Splitting a given weekly dose into more, shorter sessions versus fewer, longer sessions is itself a dosing decision with different tolerability and adherence trade-offs — shorter, more frequent bouts are sometimes better tolerated in early, more impaired patients.

Repetitions per session — the task-specific core

Repetitions are the operational unit most closely tied to the neuroplasticity dose-response evidence from Stage 2. For upper-limb motor recovery specifically, trials targeting several hundred task-specific repetitions per session (versus the 30–45 typical of unstructured usual care) have shown superior outcomes on standardized motor scales.

Repetition targets are discipline- and domain-specific: • Upper-limb motor: 100s of task-specific reps/session often cited as a meaningful threshold • Gait/lower-limb: step counts or distance-based targets (e.g., total steps per session) • Speech/aphasia: response counts, word-retrieval trials, or communicative attempts per session • Cognitive rehabilitation: trial/task repetitions calibrated to the specific cognitive domain

Because direct repetition counts are hard to standardize across every domain, weekly minutes and estimated repetitions (using domain-specific reps-per-minute heuristics) are commonly used as a practical proxy for total task-specific dose — the approach modeled by the simulator's live metrics.

A widely cited illustrative range from the stroke rehabilitation dosing literature places roughly 300–600+ minutes of task-specific therapy per week in the "optimal" zone for many patients — below which gains tend to be slower, and above which returns diminish without careful pacing (explored in Stage 4).

Fatigue and Diminishing Returns — When More Intensity Stops Helping

If task-specific repetition drives recovery, it is tempting to conclude that maximal intensity is always best. The evidence does not support this. Excessive intensity without adequate recovery degrades movement quality, increases both physical and cognitive fatigue, reduces adherence, and — in specific contexts such as very intense very-early mobilization or overly aggressive constraint-induced protocols in unsuitable candidates — has been associated with worse outcomes.

• Worse 3-mo outcome: AVERT very-early high-dose arm (vs. usual-care dosing)
• ~40–70%: Post-stroke fatigue prevalence (common comorbid symptom)
• reported at extreme dose: Movement quality decline (compensatory patterns increase)
• reduced adherence: Overtraining signal (drop-out rises with excess burden)

The plateau and downturn of the dose-response curve

The dose-response relationship explored in Stage 2 does not rise indefinitely. Beyond a patient-specific intensity threshold, additional therapy minutes or repetitions yield progressively smaller functional gains — a plateau. Push further, particularly without sufficient rest between bouts, and several problems can emerge simultaneously:

• Movement quality decline: fatigued patients recruit compensatory movement patterns (e.g., trunk substitution during reaching) that reinforce non-ideal motor strategies rather than the intended skilled movement • Reduced attention and motor learning efficiency: cognitive fatigue impairs the attention and motor-learning processes that make repetition effective in the first place — "junk reps" performed while fatigued may not drive the same plasticity as focused, effortful reps • Adherence and drop-out: therapy programs perceived as excessively burdensome show higher non-completion rates, which in practice reduces effective dose far more than a modest reduction in prescribed intensity would have • Medical and safety risk: in the acute and early subacute period particularly, excessive physiological demand can affect cardiovascular stability, and overly aggressive constraint-induced protocols in unsuitable candidates have raised safety concerns

The AVERT trial's very-early, high-frequency mobilization arm is the clearest cautionary example in the stroke literature: more sessions, delivered too early and too intensely, produced worse outcomes at three months than a more conservative dosing schedule.

Post-stroke fatigue as a dosing constraint

Fatigue is itself an extremely common post-stroke symptom, reported in roughly 40–70% of survivors and often persisting well beyond the acute phase. Unlike fatigue in healthy individuals, post-stroke fatigue can be disproportionate to activity level and slower to recover from, meaning the same nominal "dose" of therapy may represent a much larger physiological and cognitive burden for a stroke survivor than for an unaffected person.

This is why dosing frameworks increasingly build in structured rest, monitor session-to-session fatigue trends, and avoid rigid one-size-fits-all repetition targets — the same weekly minute total delivered as fewer, longer sessions with adequate recovery differs meaningfully in tolerability from the same total compressed into back-to-back high-intensity bouts.

Recognizing the overtraining signal in practice

Practical markers that a prescribed dose has crossed from optimal into counterproductive territory include: declining performance within or across sessions despite consistent effort, increasing compensatory movement patterns, disproportionate next-day fatigue or pain, falling session attendance or early termination, and patient-reported reluctance or dread toward scheduled therapy.

When these signals appear, the appropriate response in most cases is not to abandon high-intensity practice altogether — the dose-response evidence for adequate intensity remains strong — but to retitrate: adjust frequency, duration, or rest intervals while preserving task-specificity and effort, the individualized process detailed in Stage 5.

Individualized Titration and Monitoring — Closing the Feedback Loop

No fixed dosing formula applies uniformly across stroke survivors. Effective rehabilitation dosing is an iterative feedback process: a prescribed dose is delivered, functional gains and tolerance are measured, and the prescription is adjusted accordingly — accounting for time since stroke, comorbidities, and individual response — repeated across the entire recovery trajectory from acute to chronic phases.

• Acute → Subacute → Chronic: Recovery phases requiring re-titration (each favors different dosing)
• ~first 3 months: Spontaneous recovery window (largest natural gains overlap)
• still present: Chronic-phase plasticity (high-dose gains reported years out)
• session-to-session + periodic reassessment: Monitoring cadence (e.g. weekly FMA/ARAT tracking)

Titrating dose across the recovery timeline

The optimal dose is not constant over time. In the acute and early subacute phase (roughly the first weeks), spontaneous biological recovery is at its peak, medical stability is still being established, and fatigue tolerance is often lowest — favoring more conservative, carefully progressive dosing that avoids the AVERT-style pitfall of excessive very-early intensity.

As the subacute phase progresses (weeks to a few months post-stroke) and medical stability improves, tolerance for higher-intensity, higher-repetition task-specific practice typically increases, and this is often the window where aggressive dosing yields the largest incremental gains relative to standard care.

In the chronic phase (months to years post-stroke), spontaneous recovery has largely plateaued, but plasticity is not absent — high-dose, high-intensity task-specific interventions (e.g., constraint-induced movement therapy, intensive gait training) have produced meaningful gains even years after stroke, demonstrating that "chronic" does not mean "fixed."

Individual factors that modify the dosing decision

Beyond time since stroke, dosing must account for patient-specific factors:

• Comorbidities — cardiac disease, uncontrolled hypertension, diabetes-related complications, and orthopedic limitations can cap safe intensity independent of neurological status • Impairment severity — patients with severe initial deficits may need lower initial repetition counts with slower progression; those with mild deficits may tolerate — and require — much higher intensity to show measurable gains at all • Cognitive and behavioral status — attention deficits, aphasia, or depression can limit the effective dose a patient can meaningfully engage with, regardless of scheduled minutes • Social and logistic factors — transportation, caregiver support, and financial access to therapy sessions shape what dose is practically deliverable outside idealized trial conditions

A dosing plan that ignores these modifiers in favor of a single "optimal" number drawn from population-level trial data risks both undertreating patients who could tolerate more and overtraining patients who cannot.

Closing the loop — measurement-driven adjustment

Individualized titration depends on structured monitoring feeding back into the prescription:

1. Baseline and periodic reassessment: standardized scales (FMA, ARAT, gait speed, aphasia batteries) repeated at intervals (e.g., weekly to biweekly) to quantify the trajectory of functional gain, not just deliver a fixed protocol 2. Session-level tolerance tracking: fatigue ratings, pain, blood pressure/heart rate response where relevant, and observed movement quality within sessions 3. Adherence and engagement: tracking completed versus scheduled dose — a prescribed dose only produces benefit if it is actually delivered and tolerated 4. Adjustment rules: if functional gains plateau despite good tolerance, consider increasing intensity, duration, or introducing novel task variation; if fatigue markers rise or gains stall alongside declining tolerance, reduce intensity or redistribute the same weekly total across more, shorter, better-spaced sessions

This closed loop — prescribe, deliver, measure, adjust — is what allows rehabilitation dosing to approximate an individualized optimum rather than applying a single population-average prescription to every patient regardless of how they are actually responding.

The clinical goal is not to find "the" universal optimal dose, but to continuously navigate each patient toward their own optimal zone — informed by, but never rigidly bound to, the population-level dose-response evidence from Stages 2 through 4.